Tech Mahindra’s $95 Million Acquisition Of Born Group

Sullivan & Cromwell LLP advised Novartis on the acquisition.

Novartis has agreed to acquire the U.S.-based biopharmaceutical company The Medicines Company for $9.7 billion. Under the terms of the deal, Novartis will offer $85 per share in cash. The transaction is expected to close in the first quarter of 2020.

The Medicines Company focuses on researching treatments for cardiovascular disease, specifically looking at ways to lower so-called bad cholesterol. Its experimental treatment inclisiran uses a new approach to lower bad cholesterol in especially hard-to-treat patients. The treatment will join a line-up of Novartis products that includes the heart-failure treatment Entresto.

The S&C team advising Novartis is led by corporate partners Frank Aquila (Picture), Matt Hurd and Melissa Sawyer, associates Julia Kim, Natalie Lum-Tai and Franklin Liu, partners Ron Creamer (tax), Mehdi Ansari (intellectual property), Heather Coleman (executive compensation), Neal McKnight (financing), Eric Kadel (CFIUS), Renata Hesse and Michael Rosenthal (antitrust), special counsel Matt Brennan (environmental) and European counsel Foad Hoseinian (antitrust).

Involved fees earner: Mehdi Ansari – Sullivan & Cromwell; Francis Aquila – Sullivan & Cromwell; Matthew Brennan – Sullivan & Cromwell; Heather Coleman – Sullivan & Cromwell; Ronald Creamer – Sullivan & Cromwell; Renata Hesse – Sullivan & Cromwell; Foad Hoseinian – Sullivan & Cromwell; Matthew Hurd – Sullivan & Cromwell; Eric Kadel – Sullivan & Cromwell; Neal McKnight – Sullivan & Cromwell; Michael Rosenthal – Sullivan & Cromwell; Melissa Sawyer – Sullivan & Cromwell;

Law Firms: Sullivan & Cromwell;

Clients: Novartis;

Print Friendly, PDF & Email

Author: Ambrogio Visconti